Fate Therapeutics
12278 Scripps Summit Drive
San Diego
California
92131
United States
Tel: 858.875.1800
Website: http://www.fatetherapeutics.com/
Email: info@fatetherapeutics.com
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
164 articles about Fate Therapeutics
-
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 13, 2023
12/13/2023
Fate Therapeutics, Inc. announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 350,000 shares of the Company’s common stock at an exercise price per share of $2.28, which was the closing price per share of the Company’s common stock as reported by NASDAQ on the grant effective date of December 11, 2023.
-
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
11/8/2023
Fate Therapeutics, Inc. reported business highlights and financial results for the third quarter ended September 30, 2023.
-
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
10/25/2023
Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023.
-
Fate Therapeutics to Present at Upcoming September 2023 Investor Conferences
8/31/2023
Fate Therapeutics, Inc. announced that the Company will participate in the following upcoming investor conferences.
-
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
8/8/2023
Fate Therapeutics, Inc. reported business highlights and financial results for the second quarter ended June 30, 2023.
-
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
7/28/2023
Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023 at 5:00 PM ET to report its second quarter 2023.
-
Fate Therapeutics to Present at Upcoming June 2023 Investor Conferences
5/31/2023
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell -derived cellular immunotherapies to patients with cancer and autoimmune disorders, announced that the Company will participate in the following upcoming investor conferences.
-
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
5/3/2023
Fate Therapeutics, Inc. (NASDAQ: FATE) today reported business highlights and financial results for the first quarter ended March 31, 2023.
-
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
4/24/2023
Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, May 3, 2023 at 5:00 PM ET to report its first quarter 2023 financial results.
-
Fate Therapeutics to Present at Upcoming March 2023 Investor Conferences
3/3/2023
Fate Therapeutics, Inc. announced that the Company will participate in the following upcoming investor conferences:
-
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
2/28/2023
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
-
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
2/13/2023
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will host a conference call and live audio webcast on Tuesday, February 28, 2023 at 5:00 PM ET to report its fourth quarter and full year 2022 financial results and provide a corporate update.
-
Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen.
-
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
1/5/2023
Fate Therapeutics, Inc. announced that it has declined a proposal from Janssen Biotech, Inc. for continuation of the collaboration and option agreement between the parties on revised terms and conditions and, as a result, the agreement has been terminated and all collaboration activities will be wound down in the first quarter of 2023.
-
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
12/13/2022
Fate Therapeutics, Inc. presented preclinical data of several novel strategies designed to enable administration of off-the-shelf cell-based cancer immunotherapies without conditioning chemotherapy at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
-
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
12/10/2022
Fate Therapeutics, Inc. presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT576 for patients with relapsed / refractory multiple myeloma at the 64th American Society of Hematology Annual Meeting and Exposition.
-
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
12/10/2022
Fate Therapeutics, Inc. presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT819 for patients with relapsed / refractory B-cell lymphoma at the 64th American Society of Hematology Annual Meeting and Exposition.
-
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
11/7/2022
Fate Therapeutics, Inc. announced that ONO Pharmaceutical Co., Ltd. has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor T-cell product candidate targeting human epidermal growth factor receptor 2 -expressing solid tumors.
-
Fate Therapeutics to Present at Upcoming November 2022 Investor Conferences
11/4/2022
Fate Therapeutics, Inc. announced that the Company will present at the following upcoming investor conferences.
-
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
11/3/2022
Fate Therapeutics, Inc. announced that fourteen presentations for the Company’s induced pluripotent stem cell product platform were accepted for presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held in New Orleans, Louisiana, or virtually, December 10-13, 2022.